566 related articles for article (PubMed ID: 15269138)
21. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
[TBL] [Abstract][Full Text] [Related]
22. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai YH; Kuo C; Kuo MT; Chen HHW
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
[TBL] [Abstract][Full Text] [Related]
23. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.
Safaei R; Katano K; Larson BJ; Samimi G; Holzer AK; Naerdemann W; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):756-67. PubMed ID: 15701866
[TBL] [Abstract][Full Text] [Related]
24. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
25. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Song L; Li Y; Li W; Wu S; Li Z
J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
[TBL] [Abstract][Full Text] [Related]
26. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
[TBL] [Abstract][Full Text] [Related]
27. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
28. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N
Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204
[TBL] [Abstract][Full Text] [Related]
29. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
30. Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs.
Petruzzelli R; Polishchuk RS
Cells; 2019 Sep; 8(9):. PubMed ID: 31540259
[TBL] [Abstract][Full Text] [Related]
31. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
32. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
33. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
35. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
36. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Rochdi M; Howell SB
Mol Pharmacol; 2003 Aug; 64(2):466-73. PubMed ID: 12869652
[TBL] [Abstract][Full Text] [Related]
37. Functional and molecular responses of suckling rat pups and human intestinal Caco-2 cells to copper treatment.
Bauerly KA; Kelleher SL; Lönnerdal B
J Nutr Biochem; 2004 Mar; 15(3):155-62. PubMed ID: 15023397
[TBL] [Abstract][Full Text] [Related]
38. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
39. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.
Matsumoto S; Tanaka T; Kurokawa H; Matsuno K; Hayashida Y; Takahashi T
Anticancer Res; 2007; 27(4B):2209-16. PubMed ID: 17695505
[TBL] [Abstract][Full Text] [Related]
40. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]